Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

145.47 -0.63 (-0.43%)
Delayed Quote Updated: 12:47 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
Analyst Expectations for Neurocrine Biosciences's Future ↗
 
Via Benzinga
News headline image
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... 
Via Benzinga
News headline image
Analyst Ratings for Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Analyst Ratings for Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Earnings Outlook For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
What's Going On With Neurocrine Biosciences Stock Today? ↗
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due... 
Via Benzinga
News headline image
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High? ↗
The company is working on a treatment for a disorder than can cause children to begin puberty early. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning ↗
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated  
Via Benzinga
News headline image
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences ↗
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,  
Via Benzinga
News headline image
Expert Ratings for Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
News headline image
Expert Ratings for Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗
 
Via Benzinga
News headline image
3 Growth Stocks That Could Disrupt the Healthcare Industry ↗
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
News headline image
Analyst Expectations for Neurocrine Biosciences's Future ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 ↗
 
Via Benzinga
News headline image
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.